Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN2501 plus meropenem versus ceftazidime/avibactam for Gram-negative HABP/VABP
CTR20262848Phase 2Active
- Sponsor
- Joincare Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2501 in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Joincare Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
JKN2501
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20262848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262848.